Effects of pH conditions on Ca2+ transport catalyzed by ionophores A23187, 4-BrA23187, and ionomycin suggest problems with common applications of these compounds in biological systems.
Phospholipid vesicles loaded with Quin-2 and 2',7'-bis(2-carboxyethyl)-5(6)-carboxyfluorescein (BCECF) have been used to investigate the effects of pH conditions on Ca2+ transport catalyzed by ionophores A23187, 4-BrA23187, and ionomycin. At an external pH of 7.0, a delta pH (inside basic) of 0.4-0.6 U decreases the rate of Ca2+ transport into the vesicles by severalfold under some conditions. The apparent extent of transport is also decreased. In contrast, raising the pH by 0.4-0.6 U in the absence of a delta pH increases both of these parameters, although by smaller factors. The relatively large effects of a delta pH on the transport properties of Ca2+ ionophores seem to reflect a partial equilibration of the transmembrane ionophore distribution with the H+ concentration gradient across the vesicle membrane. This unequal distribution of ionophore can cause a very slow or incomplete ionophore-dependent equilibration of delta pCa with delta pH. A second factor of less certain origin retards full equilibration of delta pCa when delta pH = 0. These findings call into question several ionophore-based methods that are used to investigate the regulatory activities of Ca2+ and other divalent cations in biological systems. Notable among these are the null-point titration method for determining the concentration of free cations within cells and the use of ionophores plus external cation buffers to calibrate intracellular cation indicators. The present findings also indicate that the transport mode of Ca2+ ionophores is more strictly electroneutral than was thought, based upon previous studies.
Erdahl
W L
WL
Department of Medical Biochemistry, Ohio State University, Columbus 43210, USA.
Chapman
C J
CJ
Taylor
R W
RW
Pfeiffer
D R
DR
D000634:Aminoquinolines; D001692:Biological Transport / Q000187:drug effects; D000001:Calcimycin / Q000031:analogs & derivatives / Q000494:pharmacology*; D002118:Calcium / Q000378:metabolism*; D005452:Fluoresceins; D015759:Ionomycin / Q000494:pharmacology*; D007476:Ionophores / Q000494:pharmacology*; D007700:Kinetics; D008081:Liposomes; D008564:Membrane Potentials / Q000187:drug effects; D008954:Models, Biological; D009550:Nigericin / Q000494:pharmacology; D009994:Osmolar Concentration; D010713:Phosphatidylcholines; D013329:Structure-Activity Relationship; D014634:Valinomycin / Q000494:pharmacology
D000634:Aminoquinolines; D005452:Fluoresceins; D007476:Ionophores; D008081:Liposomes; D010713:Phosphatidylcholines; D014634:Valinomycin; D000001:Calcimycin; D015759:Ionomycin; C033170:4-bromo-A-23187; C043829:2',7'-bis(carboxyethyl)-5(6)-carboxyfluorescein; C035739:Quin2; D009550:Nigericin; D002118:Calcium; C028694:1-palmitoyl-2-oleoylphosphatidylcholine